CFIUS stalls Chinese takeover of cancer treatment provider

The Committee on Foreign Investment in the US has issued an interim order temporarily blocking a Sino Biopharm subsidiary’s $161 million acquisition of a biopharmaceutical company.

Unlock unlimited access to all Global Competition Review content